TGTX

Business Context and Reporting Period

Company: Manhattan Pharmaceuticals, Inc. (Note: Request metadata listed "TG THERAPEUTICS, INC." but the filing text identifies the registrant as Manhattan Pharmaceuticals, Inc.)
Reporting Period: Fiscal year ended December 31, 2007
Status: Clinical-stage development company with no commercial revenues.
Operations: The company focuses on developing therapies for underserved populations. Key product candidates include Hedrin (head lice), Topical PTH (1-34) (psoriasis), Altoderm (atopic dermatitis), and Altolyn (mastocytosis). In 2007, the company discontinued development of Oleoyl-estrone and Propofol Lingual Spray following negative clinical trial results.

Key Financial Metrics

Liquidity: The company reported a net decrease in cash of approximately $2.38 million in 2007. As of December 31, 2007, total liquid resources were approximately $650,000. The company has a working capital deficit of approximately $1.0 million.

Material Changes vs. Prior Period

• Increased Net Loss: Net loss increased by approximately $2.34 million (24.1%) compared to 2006, primarily driven by a $2.0 million increase in in-license, milestone, and related fees.
• R&D Expense Growth: R&D expenses rose 38.3% to $8.54 million, largely due to new licensing agreements for Hedrin, Altoderm, and Altolyn, and the achievement of a Phase 2 milestone for Topical PTH (1-34).
• Cash Burn: Cash used in operating activities was $10.23 million in 2007, compared to $7.75 million in 2006.
• Program Discontinuations: The company halted development of Oleoyl-estrone and Propofol Lingual Spray in July 2007 after Phase 2a trials failed to show statistically meaningful results.

Guidance, Outlook, Risks, and Unusual Items

Outlook and Capital Needs: Management stated that as of December 31, 2007, the company did not have sufficient capital to fund operations through the end of 2008. The company expects to continue incurring net losses and negative cash flows for the foreseeable future. Additional equity or debt financing is required to sustain operations and complete product development.

Subsequent Event (Joint Venture): In February 2008, the company entered a 50/50 joint venture with Nordic Biotech Advisors ApS to develop and commercialize Hedrin. The company received net proceeds of approximately $2.0 million from this transaction. The JV assumes responsibility for all costs associated with the Hedrin project.

Delisting: The company voluntarily delisted from the American Stock Exchange (AMEX) effective March 26, 2008, due to non-compliance with listing standards (stockholders' equity and net losses). It now trades on the OTC Bulletin Board under the symbol "MHAN".

Risks and Contingencies:

• Going Concern: The auditor's report raises substantial doubt about the company's ability to continue as a going concern due to recurring losses and negative cash flows.
• Legal Proceedings: A clinical site, Swiss Pharma Contract LTD, has filed for arbitration claiming an additional $322,776 for services. The company disputes this claim and has not accrued the cost.
• Regulatory Risk: No products have received FDA approval. Success depends on clinical trial results and regulatory acceptance.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $2.0 million received from the February 2008 Hedrin joint venture to fund operations through 2008, given the stated need for additional financing.
• Joint Venture Terms: Review the specific terms of the Hedrin JV, including the "put" and "call" options that could result in significant dilution of existing shareholders.
• Legal Exposure: Monitor the status of the arbitration with Swiss Pharma Contract LTD regarding the $322,776 claim.
• Clinical Milestones: Track the progress of the Phase 2a trial for Topical PTH (1-34) and the regulatory status of Hedrin as a medical device.
• Stock Liquidity: Assess the impact of the delisting from AMEX to the OTC Bulletin Board on stock liquidity and trading volume.